Financings Of The Fortnight: VCs May Be Up Against Trend Of Eliminating The “Middle-Man”
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by PharmAria, Inception 3, Longitude Capital, Kythera and Intercept.
You may also be interested in...
Genocea Gets An Injection Of Capital As Early-Stage Studies Progress
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
Mid-To-Late-Stage Investor Longitude Capital Closes $385M Second Fund
A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”
Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.